E2F1‑induced microRNA‑224‑5p expression is associated with hepatocellular carcinoma cell migration, invasion and epithelial‑mesenchymal transition via MREG

Li,An; Wu,Ning; Sun,Jingyu

doi:10.3892/ol.2022.13202

E2F1‑induced microRNA‑224‑5p expression is associated with hepatocellular carcinoma cell migration, invasion and epithelial‑mesenchymal transition via MREG

Authors:
- An Li
- Ning Wu
- Jingyu Sun
View Affiliations

Affiliations: Department of Radiotherapy, Shanxi Yuncheng Central Hospital, Yuncheng, Shanxi 044000, P.R. China, Department of Oncology, Shanghai Pudong New Area Gongli Hospital, Shanghai 200135, P.R. China, Department of Cardiology, Shanxi Yuncheng Central Hospital, Yuncheng, Shanxi 044000, P.R. China
Published online on: January 17, 2022 https://doi.org/10.3892/ol.2022.13202
Article Number: 82
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)‑224‑5p has been reported to be associated with multiple types of cancer. However, its biological role and underlying mechanism in hepatocellular carcinoma (HCC) has yet to be fully elucidated. The aim of the present study was to investigate whether miR‑224‑5p mRNA expression level was increased in hepatocellular carcinoma and whether it was associated with poor prognosis. Decreased mRNA expression level of miR‑224‑5p was shown to suppress liver cancer cell migration, invasion and epithelial‑mesenchymal transition (EMT). Mechanistically, E2F1 was found to regulate miR‑224‑5p expression by binding to its promoter region. Melanoregulin (MREG) was identified as the direct target of miR‑224‑5p by searching the TargetScan, miRDB and StarBase databases. Overexpression of MREG could attenuate liver cancer cell migration, invasion and EMT. Rescue experiments further confirmed that MREG was associated with the regulation of miR‑224‑5p in liver cancer. In addition, the E2F1/miR‑224‑5p axis was shown to promote liver cancer cell migration, invasion and EMT by regulating MREG expression. These results suggested that E2F1‑induced upregulation of miR‑224‑5p may serve an important role in MREG‑induced liver cancer cell migration, invasion and EMT, and highlights the regulatory function of miR‑224‑5p in liver cancer. Therefore, the E2F1/miR‑224‑5p/MREG axis may provide a theoretical basis for the clinical treatment of hepatocellular carcinoma.

View Figures

View References

1	Budhu A, Forgues M, Ye QH, Jia HL, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY and Wang XW: Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell. 10:99–111. 2006. View Article : Google Scholar : PubMed/NCBI
2	Taketomi A, Toshima T, Kitagawa D, Motomura T, Takeishi K, Mano Y, Kayashima H, Sugimachi K, Aishima S, Yamashita Y, et al: Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 17:2740–2746. 2010. View Article : Google Scholar : PubMed/NCBI
3	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
4	Xiao S, Chang RM, Yang MY, Lei X, Liu X, Gao WB, Xiao JL and Yang LY: Actin-like 6A predicts poor prognosis of hepatocellular carcinoma and promotes metastasis and epithelial-mesenchymal transition. Hepatology. 63:1256–1271. 2016. View Article : Google Scholar : PubMed/NCBI
5	Deng GL, Zeng S and Shen H: Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges. World J Hepatol. 7:787–798. 2015. View Article : Google Scholar : PubMed/NCBI
6	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
7	Ogunwobi OO, Harricharran T, Huaman J, Galuza A, Odumuwagun O, Tan Y, Ma GX and Nguyen MT: Mechanisms of hepatocellular carcinoma progression. World J Gastroenterol. 25:2279–2293. 2019. View Article : Google Scholar : PubMed/NCBI
8	Maluccio M and Covey A: Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma. CA Cancer J Clin. 62:394–399. 2012. View Article : Google Scholar : PubMed/NCBI
9	Morise Z, Kawabe N, Tomishige H, Nagata H, Kawase J, Arakawa S, Yoshida R and Isetani M: Recent advances in the surgical treatment of hepatocellular carcinoma. World J Gastroenterol. 20:14381–14392. 2014. View Article : Google Scholar : PubMed/NCBI
10	Gallicchio R, Nardelli A, Mainenti P, Nappi A, Capacchione D, Simeon V, Sirignano C, Abbruzzi F, Barbato F, Landriscina M and Storto G: Therapeutic strategies in HCC: Radiation modalities. Biomed Res Int. 2016:12953292016. View Article : Google Scholar : PubMed/NCBI
11	Giannelli G, Koudelkova P, Dituri F and Mikulits W: Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
12	Filipowicz W, Bhattacharyya SN and Sonenberg N: Mechanisms of post-transcriptional regulation by microRNAs: Are the answers in sight. Nat Rev Genet. 9:102–114. 2008. View Article : Google Scholar : PubMed/NCBI
13	Chai S, Ng KY, Tong M, Lau EY, Lee TK, Chan KW, Yuan YF, Cheung TT, Cheung ST, Wang XQ, et al: Octamer 4/microRNA-1246 signaling axis drives Wnt/β-catenin activation in liver cancer stem cells. Hepatology. 64:2062–2076. 2016. View Article : Google Scholar : PubMed/NCBI
14	Zhang S and Ng MK: Gene-microRNA network module analysis for ovarian cancer. BMC Syst Biol. 10 (Suppl 4):S1172016. View Article : Google Scholar
15	Chen J, Zhang H, Chen Y, Qiao G, Jiang W, Ni P, Liu X and Ma L: miR-598 inhibits metastasis in colorectal cancer by suppressing JAG1/Notch2 pathway stimulating EMT. Exp Cell Res. 352:104–112. 2017. View Article : Google Scholar : PubMed/NCBI
16	Peng Y, Zhang X, Ma Q, Yan R, Qin Y, Zhao Y, Cheng Y, Yang M, Wang Q, Feng X, et al: MiRNA-194 activates the Wnt/β-catenin signaling pathway in gastric cancer by targeting the negative Wnt regulator, SUFU. Cancer Lett. 385:117–127. 2017. View Article : Google Scholar : PubMed/NCBI
17	Zhao Z, Fan X, Jiang L, Xu Z, Xue L, Zhan Q and Song Y: miR-503-3p promotes epithelial-mesenchymal transition in breast cancer by directly targeting SMAD2 and E-cadherin. J Genet Genomics. 44:75–84. 2017. View Article : Google Scholar : PubMed/NCBI
18	Zhu J, Zeng Y, Li W, Qin H, Lei Z, Shen D, Gu D, Huang JA and Liu Z: CD73/NT5E is a target of miR-30a-5p and plays an important role in the pathogenesis of non-small cell lung cancer. Mol Cancer. 16:342017. View Article : Google Scholar : PubMed/NCBI
19	O'Sullivan TN, Wu XS, Rachel RA, Huang JD, Swing DA, Matesic LE, Hammer JA III, Copeland NG and Jenkins NA: dsu functions in a MYO5A-independent pathway to suppress the coat color of dilute mice. Proc Natl Acad Sci USA. 101:16831–16836. 2004. View Article : Google Scholar : PubMed/NCBI
20	Wang C, Zhu J, Zhang Z, Chen H, Ji M, Chen C, Hu Y, Yu Y, Xia R, Shen J, et al: Rno-miR-224-5p contributes to 2,2′,4,4′-tetrabromodiphenyl ether-induced low triiodothyronine in rats by targeting deiodinases. Chemosphere. 246:1257742020. View Article : Google Scholar : PubMed/NCBI
21	Qiao W, Li D, Shi Q, Wang H, Wang H and Guo J: miR-224-5p protects dental pulp stem cells from apoptosis by targeting Rac1. Exp Ther Med. 19:9–18. 2020.PubMed/NCBI
22	Zang CS, Huang HT, Qiu J, Sun J, Ge RF and Jiang LW: MiR-224-5p targets EGR2 to promote the development of papillary thyroid carcinoma. Eur Rev Med Pharmacol Sci. 24:4890–4900. 2020.PubMed/NCBI
23	Peng X, Guo C, Wu Y, Ying M, Chang R, Song L, Zhan L and Zhan X: miR-224-5p regulates the proliferation, migration and invasion of pancreatic mucinous cystadenocarcinoma by targeting PTEN. Mol Med Rep. 23:3462021. View Article : Google Scholar : PubMed/NCBI
24	Qin Z, Hu H, Sun W, Chen L, Jin S, Xu Q, Liu Y, Yu L and Zeng S: miR-224-5p contained in urinary extracellular vesicles regulates PD-L1 expression by inhibiting cyclin D1 in renal cell carcinoma cells. Cancers (Basel). 13:6182021. View Article : Google Scholar : PubMed/NCBI
25	Wang Y, Wang P, Zhao L, Chen X, Lin Z, Zhang L and Li Z: miR-224-5p carried by human umbilical cord mesenchymal stem cells-derived exosomes regulates autophagy in breast cancer cells via HOXA5. Front Cell Dev Biol. 9:6791852021. View Article : Google Scholar : PubMed/NCBI
26	Li J, Liu X, Li C and Wang W: miR-224-5p inhibits proliferation, migration, and invasion by targeting PIK3R3/AKT3 in uveal melanoma. J Cell Biochem. 120:12412–12421. 2019. View Article : Google Scholar : PubMed/NCBI
27	Gan BL, Zhang LJ, Gao L, Ma FC, He RQ, Chen G, Ma J, Zhong JC and Hu XH: Downregulation of miR-224-5p in prostate cancer and its relevant molecular mechanism via TCGA, GEO database and in silico analyses. Oncol Rep. 40:3171–3188. 2018.PubMed/NCBI
28	Zheng SQ, Qi Y, Wu J, Zhou FL, Yu H, Li L, Yu B, Chen XF and Zhang W: CircPCMTD1 acts as the sponge of miR-224-5p to Promote glioma progression. Front Oncol. 9:3982019. View Article : Google Scholar : PubMed/NCBI
29	Miao K, Liu SD, Huang WX and Dong H: MiR-224 executes a tumor accelerative role during hepatocellular carcinoma malignancy by targeting cytoplasmic polyadenylation element-binding protein 3. Pharmacology. 105:477–487. 2020. View Article : Google Scholar : PubMed/NCBI
30	Yang L, Wei C, Li Y, He X and He M: miR-224 is an early-stage biomarker of hepatocellular carcinoma with miR-224 and miR-125b as prognostic biomarkers. Biomark Med. 14:1485–1500. 2020. View Article : Google Scholar : PubMed/NCBI
31	Wu M, Deng X, Zhong Y, Hu L, Zhang X, Liang Y, Li X and Ye X: MafF is regulated via the circ-ITCH/miR-224-5p axis and acts as a tumor suppressor in hepatocellular carcinoma. Oncol Res. 28:299–309. 2020. View Article : Google Scholar : PubMed/NCBI
32	Ma D, Tao X, Gao F, Fan C and Wu D: miR-224 functions as an onco-miRNA in hepatocellular carcinoma cells by activating AKT signaling. Oncol Lett. 4:483–488. 2012. View Article : Google Scholar : PubMed/NCBI
33	Damek-Poprawa M, Diemer T, Lopes VS, Lillo C, Harper DC, Marks MS, Wu Y, Sparrow JR, Rachel RA, Williams DS and Boesze-Battaglia K: Melanoregulin (MREG) modulates lysosome function in pigment epithelial cells. J Biol Chem. 284:10877–10889. 2009. View Article : Google Scholar : PubMed/NCBI
34	Ohbayashi N, Maruta Y, Ishida M and Fukuda M: Melanoregulin regulates retrograde melanosome transport through interaction with the RILP-p150Glued complex in melanocytes. J Cell Sci. 125:1508–1518. 2012.PubMed/NCBI
35	Meng X, Dong Y, Yu X, Wang D, Wang S, Chen S and Pang S: MREG suppresses thyroid cancer cell invasion and proliferation by inhibiting Akt-mTOR signaling. Biochem Biophys Res Commun. 491:72–78. 2017. View Article : Google Scholar : PubMed/NCBI
36	Fornes O, Castro-Mondragon JA, Khan A, van der Lee R, Zhang X, Richmond PA, Modi BP, Correard S, Gheorghe M, Baranašić D, et al: JASPAR 2020: Update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 48:D87–D92. 2020.PubMed/NCBI
37	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
38	Knoll S, Fürst K, Kowtharapu B, Schmitz U, Marquardt S, Wolkenhauer O, Martin H and Pützer BM: E2F1 induces miR-224/452 expression to drive EMT through TXNIP downregulation. EMBO Rep. 15:1315–1329. 2014. View Article : Google Scholar : PubMed/NCBI
39	Farra R, Grassi G, Tonon F, Abrami M, Grassi M, Pozzato G, Fiotti N, Forte G and Dapas B: The role of the transcription factor E2F1 in hepatocellular carcinoma. Curr Drug Deliv. 14:272–281. 2017.PubMed/NCBI
40	Zhu Q, Gong L, Wang J, Tu Q, Yao L, Zhang JR, Han XJ, Zhu SJ, Wang SM, Li YH and Zhang W: miR-10b exerts oncogenic activity in human hepatocellular carcinoma cells by targeting expression of CUB and sushi multiple domains 1 (CSMD1). BMC Cancer. 16:8062016. View Article : Google Scholar : PubMed/NCBI
41	Anastasiadou E, Jacob LS and Slack FJ: Non-coding RNA networks in cancer. Nat Rev Cancer. 18:5–18. 2018. View Article : Google Scholar : PubMed/NCBI